Clinical Trials - May 30, 2022
AlzeCure gets approval to start Phase II clinical trial
AlzeCure Pharma has received approval from the regulatory authorities in Sweden to initiate its clinical phase IIa study with the drug candidate ACD440 in patients with peripheral neuropathic pain. ”We now have all regulatory approvals in place to be able to start the phase IIa study with ACD440. We expect to be able to initiate […]
Nobel Prize Discoveries - April 24, 2022
Unlocking the door to a complex sense
The Nobel Laureates in Medicine 2021 revealed the mechanisms that underpin the different sensations of temperature and touch. Their discoveries have led to a better understanding of how the nervous system codes sensory information, as well as triggering a myriad of exciting new questions. Since the 1940s, it has been demonstrated that nerve cells are […]
Financing - April 12, 2022
AlzeCure Pharma carries out a set-off issue
The company is carrying out a set-off issue of 845,070 shares to Acturum Life AB as a result of a previously agreed milestone payment, which will be made in the form of shares instead of cash payment. “The set-off issue strengthens the company’s liquidity and we are pleased that Acturum Life chooses to show its […]
Clinical Trials - February 9, 2022
AlzeCure receives FDA response regarding preIND application
AlzeCure Pharma has received a response from the US Food and Drug Administration (FDA) regarding the preIND application that was submitted prior to the planned phase IIa study with ACD440 in neuropathic pain. ACD440 completed a positive phase Ib study in 2021 and the company now plans to initiate a clinical phase IIa study in […]
Drug Development Pharma - October 5, 2021
AlzeCure Pharma presents new data
AlzeCure Pharma has presented new data showing how substances from the NeuroRestore platform affect relevant signaling pathways in the brain and have effects in various preclinical models that link to depression. “The findings we have seen with our substances indicate that there are also great opportunities for the NeuroRestore platform in other cognitive disorders outside […]
Biotech Business - August 30, 2021
AlzeCure receives approval from the Medical Products Agency
The company has received approval to be able to give additional doses of ACD856 in their clinical phase I study (single ascending dose, SAD) with ACD856, as its good tolerability enables higher doses to be tested. Data from the SAD study establish that ACD856, the lead candidate drug within the company’s NeuroRestore platform, shows good […]
